Last reviewed · How we verify
Autologous MUC1-activated T-cells
At a glance
| Generic name | Autologous MUC1-activated T-cells |
|---|---|
| Also known as | Autologous MUC1-activated T-lymphocytes |
| Sponsor | Mayo Clinic |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (PHASE1)
- Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma (PHASE1)
- PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous MUC1-activated T-cells CI brief — competitive landscape report
- Autologous MUC1-activated T-cells updates RSS · CI watch RSS
- Mayo Clinic portfolio CI